Search
for

    Glossary Belimumab

    monoclonal antibody targeting B-lymphocyte stimulator for autoimmune conditions

    Belimumab is a monoclonal antibody that inhibits the activity of B-lymphocyte stimulator (BLyS), a protein involved in the survival and proliferation of B cells. It is primarily used in the treatment of systemic lupus erythematosus (SLE) but has gained attention for its potential role in hair loss conditions, particularly in cases of autoimmune-related alopecia. By modulating the immune response, belimumab may help reduce inflammation and promote hair regrowth in individuals experiencing hair loss due to autoimmune disorders. Its distinguishing characteristic is its targeted action on the immune system, differentiating it from other hair loss treatments that focus on hormonal or topical interventions.

    Research 10 of 61

    1. Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study Seminars in Arthritis and Rheumatism · 2018 · 70 citations
    2. AB0442 Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort 2017 · 2 citations
    3. PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort Reumatismo · 2025
    4. PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort DOAJ (DOAJ: Directory of Open Access Journals) · 2025
    5. Alopecia Areata Following the Use of Belimumab in a Patient with Systemic Lupus Erythematosus and Arthritis Who Responded Well to Baricitinib: A Case Report American Journal of Case Reports · 2024
    6. POS0548 ACUTE AND SUBACUTE SKIN MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS ARE ASSOCIATED WITH AN EARLIER RESPONSE TO BELIMUMAB THAN THE CHRONIC PHENOTYPE: PRELIMINARY DATA FROM THE NEW NATION-WIDE COHORT OF BELIMUMAB IN REAL LIFE SETTING STUDY—NEW JOINT AND SKIN (BERLISS-NEJS) 2024
    7. Alopecia areata after belimumab use in a patient with systemic lupus erythematosus: a paradoxical case of autoimmunity 2024
    8. FRI0310 Achievement of low disease activity in lupus patients treated with belimumab is independent of serologic status at baseline: a real-life observational study 2018
    9. The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket Immunosuppressives 2024
    10. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults Rheumatology · 2017 · 213 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →